The economic burden of progressive chronic kidney disease among patients with type 2 diabetes

Journal of Diabetes and its Complications

Volumn 28, Issue 1, 2014, Pages 10-16

  Vupputuri, Suma ^a   Kimes, Teresa M ^b   Calloway, Michael O ^c   Christian, Jennifer B ^c   Bruhn, David ^c   Martin, Alan A ^c   Nichols, Gregory A ^b  

^a Center for Health Research   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Chronic kidney disease; Costs; Diabetes mellitus; Health care economics

Indexed keywords

CREATININE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COST OF ILLNESS; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; EVALUATION AND FOLLOW UP; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; AGED; COMPLICATION; DIABETES MELLITUS, TYPE 2; ECONOMICS; INCIDENCE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; TRENDS; UNITED STATES;

AGED; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84891829578     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2013.09.014     Document Type: Article

References (34)

1. C.M. Alexander, P.A. Lyle, W.F. Keane, G.W. Carides, Z. Zhang, and S. Shahinfar Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy Kidney International. Supplement 92 2004 S115 S117
2. American Diabetes Association Standards of medical care in diabetes - 2011 Diabetes Care 2011 S11 S61
3. G.L. Bakris Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus Mayo Clinic Proceedings 86 5 2011 444 456
4. L.D. Bash, E. Selvin, M. Steffes, J. Coresh, and B.C. Astor Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study Archives of Internal Medicine 168 22 2008 2440 2447
5. J.P. Boyle, T.J. Thompson, E.W. Gregg, L.E. Barker, and D.F. Williamson Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence Popul Health Metr 8 2010 29
6. A. Briggs, R. Nixon, S. Dixon, and S. Thompson Parametric modelling of cost data: Some simulation evidence Health Economics 14 4 2005 421 428
7. J.B. Brown, G.A. Nichols, H.S. Glauber, and A.W. Bakst Type 2 diabetes: Incremental medical care costs during the first 8 years after diagnosis Diabetes Care 22 7 1999 1116 1124
8. J.B. Brown, K.L. Pedula, and A.W. Bakst The progressive cost of complications in type 2 diabetes mellitus Archives of Internal Medicine 159 16 1999 1873 1880
9. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven et al. Glucose control and vascular complications in veterans with type 2 Diabetes New England Journal of Medicine 360 2008 129 131
10. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet 355 9200 2000 253 259
11. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, and J. Beutler et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis New England Journal of Medicine 360 2009 1395 1407
12. H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff Jr., J.T. Bigger, and J.B. Buse et al. Effects of intensive glucose lowering in type 2 diabetes New England Journal of Medicine 358 2008 2545 2559
13. M.C. Hornbrook, M.J. Goodman, P.A. Fishman, R.T. Meenan, M. O'Keeffe-Rosetti, and D.J. Bachman Building health plan databases to risk adjust outcomes and payments International Journal for Quality in Health Care 10 6 1998 531 538
14. J.H. Ix Hemoglobin A1c in hemodialyis patients: Should one size fit all? Clinical Journal of the American Society of Nephrology 5 2010 1539 1541
15. B.L. Jaber, and N.E. Madias Progression of chronic kidney disease: Can it be prevented or arrested? American Journal of Medicine 118 12 2005 1323 1330
16. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease American Journal of Kidney Diseases 49 2 Suppl 2 2007 S12 S154
17. M.J. Klag, P.K. Whelton, and B.L. Randall et al. Blood pressure and end-stage renal disease in men New England Journal of Medicine 334 1 1996 13 18
18. C.E. Koro, B.H. Lee, and S.J. Bowlin Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States Clinical Therapeutics 31 11 2009 2608 2617
19. F. Laliberte, B.K. Bookhart, and F. Vekeman et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: A managed care perspective Journal of Managed Care Pharmacy 15 4 2009 312 322
20. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes New England Journal of Medicine 345 12 2001 851 860
21. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease American Journal of Kidney Diseases 49 2 Suppl 2 2007 S12 S154
22. G.A. Nichols, S. Vupputuri, and H. Lau Medical care costs associated with progression of diabetic nephropathy Diabetes Care 34 11 2011 2374 2378
23. H.H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, and P. Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes New England Journal of Medicine 345 12 2001 870 878
24. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, and M. Woodward et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes New England Journal of Medicine 358 2008 2560 2572
25. E.M. Pelletier, P.J. Smith, K.S. Boye, D.A. Misurski, S.L. Tunis, and M.E. Minshall Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: A resource for economic research Applied Health Economics and Health Policy 6 2-3 2008 103 112
26. L.C. Plantinga, D.C. Crews, and J. Coresh et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes Clinical Journal of the American Society of Nephrology 5 4 2010 673 682
27. L.C. Plantinga, E.R. Miller 3rd, and L.A. Stevens et al. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006 Hypertension 54 1 2009 47 56
28. G. Remuzzi, M. Macia, and P. Ruggenenti Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study Journal of the American Society of Nephrology 17 4 Suppl 2 2006 S90 S97
29. J.V. Selby, G.T. Ray, D. Zhang, and C.J. Colby Excess costs of medical care for patients with diabetes in a managed care population Diabetes Care 20 9 1997 1396 1402
30. S. Shurraw, B. Hemmelgarn, and M. Lin et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: A population-based cohort study Archives of Internal Medicine 171 21 2011 1920 1927
31. D.H. Smith, C.M. Gullion, G. Nichols, D.S. Keith, and J.B. Brown Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population Journal of the American Society of Nephrology 15 5 2004 1300 1306
32. US renal data system. USRDS annual data report. Atlas of end-stage renal disease in the United States 2010 National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, MD
33. S. Vupputuri, G.A. Nichols, H. Lau, P. Joski, and M.L. Thorp Risk of progression of nephropathy in a population-based sample with type 2 diabetes Diabetes Research and Clinical Practice 91 2 2011 246 252
34. C. Wanner, V. Krane, W. Marz, M. Olschewski, J.F. Mann, and G. Ruf et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis New England Journal of Medicine 353 2005 238 248